Wegovy (Semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist formulated for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity. As the 0.25mg initiation dose, it provides controlled physiological support to prime the metabolic system and minimize gastrointestinal side effects during the first four weeks of therapy.

Dosage & Administration

• Dosage: Adhere strictly to the dosing schedule and administration instructions provided by your physician.
• Method: Subcutaneous injection into the abdomen, thigh, or upper arm.
• Cycle: One FlexTouch pen contains 4 initiation doses.

Technical Specification

• Form: Multi-dose pre-filled delivery device (FlexTouch).
• Active Ingredient: Semaglutide.
• Included Components: 1 pre-filled pen and 4 disposable needles.

Ingredient Functionality

• Semaglutide: A GLP-1 analogue that acts as a receptor agonist. It increases metabolic efficiency by mimicking natural incretin hormones, facilitating long-term weight reduction.
• Satiety Induction: Targets the brain's appetite regulation centers to decrease hunger and increase feelings of fullness.
• Glycemic Regulation: Enhances glucose-dependent insulin secretion and inhibits glucagon release, promoting stable blood sugar levels.

Safety & Storage

• Unopened Storage: Refrigerate at 2°C to 8°C. Do not freeze or use if the product has been frozen.
• In-Use Storage: Following the first dose, the pen can be stored for up to 6 weeks at room temperature (below 30°C) or in the refrigerator.
• Visual Standards: The solution must be clear and colorless.